ERBB2 and breast carcinoma: Another study from the American College of Surgeons Oncology Group Z1041 trial showed that activated immune signatures, including T-cell, B-cell, and inflammatory signatures were enriched in cases that achieved a pCR in HER2-positive breast cancer patients who received neoadjuvant chemotherapy and trastuzumab [40].